Analysis of the Global AI in Clinical Trials Industry, 2023 to 2035 - Product/Technology Utilization and Integration Agreements Lead the Way in Partnerships

DUBLIN, Aug. 25, 2023 /PRNewswire/ -- The "Global AI in Clinical Trials Market: Trends and Forecasts 2023-2035" report has been added to ResearchAndMarkets.com's offering.

The global AI in clinical trials market is estimated to be worth $ 1.4 billion in 2023 and expected to grow at compounded annual growth rate (CAGR) of 16% during the forecast period.

The process of successfully developing a novel therapeutic intervention is both time and cost intensive. In fact, it is estimated that a drug requires around 10 years and over $ 2.5 billion capital investment, before reaching the market. In this process, clinical trials play a crucial role for assessing the drug's efficacy and safety in humans. These trials account for nearly 50% of the time and capital expenditure during drug development. However, sponsors face financial burdens and significant delays in marketing drugs due to unsuccessful clinical trials.

Over the past few decades, the success rate of a drug candidate advancing the clinical trials to obtaining marketing approval has remained relatively constant at approximately 10% - 20%. This can be attributed to the factors contributing to clinical stage intervention failure, including inadequate study design, incomplete patient recruitment, improper subject stratification and high rate of clinical trial participant attrition.

In order to overcome these challenges and streamline the clinical trial processes, stakeholders in the pharmaceutical industry are exploring innovative solutions and strategies. One such innovative strategy involves integrating AI in drug development, which has the potential to revolutionize traditional methods, particularly in clinical trials. It is worth noting that artificial intelligence in clinical trials can help integrate and analyze large volumes of data, enabling trial sponsors to optimize future research initiatives. Additionally, by addressing issues related to trial design, patient recruitment and retention, site selection, data interpretation, and treatment evaluation, AI has the potential to enhance and refine the entire process of clinical drug development.

Moreover, in the first nine months of 2021, more than $20 billion was invested into artificial intelligence companies focused on healthcare, exceeding the prior investment, which was around $15 billion in 2020. Therefore, with the rising interest of investors in this field, we anticipate the AI in clinical trials market to witness healthy growth during the forecast period.

Key Market Insights

The report features an extensive study of the current market landscape, market size and future opportunities associated with the AI in clinical trials market, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the AI in clinical trials market report are briefly discussed below.

Benefits and Growing Demand for Artificial Intelligence Solutions for Patient Recruitment and Clinical Data Analysis

AI solutions have emerged as a promising tool in the drug development process. These AI tools help companies improve the accuracy and efficiency of testing, accelerate drug development and optimize clinical trial outcomes. In addition, leveraging AI software in clinical trials helps increasing patient recruitment and retention, reduces trial time and cost, and provides more accurate clinical data analysis, personalized medicine, trial design and real-time patient monitoring.

It is worth highlighting that the ability of AI to automate and streamline labor-intensive tasks, improve decision-making processes, and identify patterns and trends in complex datasets has garnered significant attention and interest from stakeholders in the pharmaceutical industry. In May 2023, US based Owkin received letter of support from the European Medicines Agency (EMA) for the use of proprietary deep learning models for oncology clinical trial analysis; the company believes that this can reduce the clinical trial failure rates in randomized clinical trial. Further several artificial intelligence companies have developed AI-powered platforms that optimize patient identification for clinical trials. Additionally, AI algorithms can be trained to analyze large amounts of data in electronic health records to identify eligible participants.

Owing to these applications and recognition of the immense potential of AI by researchers and sponsors, the demand for AI clinical trials is likely to continue to grow and transform the landscape of drug development by improving patient outcomes in clinical trials.

Current Market Landscape of AI in Clinical Trials: AI Software and Service Providers

The AI in clinical trials market landscape features a mix of large, mid-sized and small companies. Currently, around 130 players have the required expertise to offer various software and services to streamline clinical studies. Notably, at present, around 80% of these AI in clinical trials software and service providers are focusing on leveraging machine learning and deep learning algorithms, as they minimize data-based errors by accessing various data points simultaneously. Recent developments in this field indicate that the artificial intelligence companies in clinical trials are upgrading their capabilities to accommodate the current and anticipated demand for these software and services.

Partnership and Collaboration Trends in the AI in Clinical Trials Market

In recent years, several artificial intelligence companies have inked partnerships related to AI in clinical trials domain with other industry / non-industry players. It is worth highlighting that, since 2018, a significant number of strategic partnerships have been inked in the AI in clinical trials industry. It is worth highlighting that product / technology utilization and integration agreements are the most common types of partnerships inked by stakeholders in the AI clinical trials field.

Owing to several advantages of artificial intelligence in clinical trials, stakeholders are acquiring other industry players offering AI solutions / AI software for different clinical trial applications in order to expand their capabilities and build a comprehensive product / service portfolio. In February 2023, ZS acquired Trials.ai, an intelligent study design company, to enhance its end-to-end solutions to reimagine study design for its clients. In addition, several big pharma companies, such as Bristol Myers Squibb, GlaxoSmithKline (GSK), Johnson & Johnson, Merck, Pfizer and Roche, have also taken partnership initiatives related to AI in clinical trials, indicating the promise and benefits that AI technology holds in clinical trials.

Key Trends in the AI in Clinical Trials Market

In the past six years, around 600 completed / ongoing clinical trials utilized AI tools and technologies for evaluating drugs / therapies for different therapeutic areas, indicating the substantial efforts made by researchers engaged in this domain. Further, most of the clinical studies were designed for the purpose of diagnostics and treatment. It is worth noting that the University of California, the National Institute of Allergy and Infectious Diseases, and Mayo Clinic are among the most active sponsors of completed / ongoing clinical trials involving AI solutions.

Rise in Investment in AI in Clinical Trials Market

The heightened interest in the AI in clinical trials market can be validated by the fact that, in the last five years, close to $2.5 billion has been invested in companies engaged in providing AI software and services for clinical trials by several investors based across the globe. The majority of the funds have been raised through venture rounds, followed by seed financing rounds. In addition, several big pharma players, such as Bristol Myers Squibb, Merck, Novartis, Pfizer and Sanofi have also invested in AI software and service providers for clinical trials. In June 2021, Antidote Technologies raised $23 million to expand its digital patient engagement programs and clinical trial recruitment services.

AI in Clinical Trials Market Size

Driven by the rising demand for artificial intelligence in clinical trials, lucrative opportunities are expected to emerge for players offering AI technology for clinical studies. The global market for AI in clinical trials is anticipated to grow at a significant pace, with a CAGR of 16% during the forecast period. Among the therapeutic areas for which AI tools are leveraged in clinical trials, oncological disorders are most likely to adopt these AI solutions for streamlining processes, such as patient recruitment and retention, trial design, site selection, clinical data analysis, patient monitoring and personalized treatment. In terms of end-users, biotechnology and pharmaceutical companies are likely to hold the majority share (75%) of the AI in clinical trials market.

Key Artificial Intelligence Companies Supporting Clinical Trials

Examples of the key companies engaged in the AI in clinical trials domain (the complete list of players is available in the full report) include (in alphabetic order) Acclinate, AiCure, Aidar Health, Aitia, A.I. VALI, Ancora.ai, Antidote Technologies, Beacon Biosignals, BUDDI.AI, ConcertAI, Curify, Deep 6 AI, ICON, Innoplexus, Massive Bio, Median Technologies, Novadiscovery, Owkin, PHASTAR, SiteRx and Viz.ai. This market report also includes an easily searchable excel database of all the AI software / AI solutions and service providers for clinical trials worldwide.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments. The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies. The opinions and insights presented in the report were influenced by discussions held with stakeholders in this industry.

The report also features detailed transcripts of interviews held with various industry stakeholders:

• Danielle Ralic (Co-Founder, Chief Executive Officer and Chief Technology Officer, Ancora.ai)
• Wout Brusselaers (Founder and Chief Executive Officer, Deep 6 AI)
• Dimitrios Skaltsas (Co-Founder and Executive Director, Intelligencia)
• R. A. Bavasso (Founder and Chief Executive Officer, nQ Medical)
• Grazia Mohren (Head of Marketing), Michael Shipton (Chief Commercial Officer), Darcy Forman (Chief Delivery Officer), Troy Bryenton (Chief Technology Officer, Science 37)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions.

Key Topics Covered

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Artificial Intelligence (AI)
3.3. Subfields of AI
3.4. Applications of AI in Healthcare
3.4.1. Drug Discovery
3.4.2. Drug Manufacturing
3.4.3. Marketing
3.4.4. Diagnosis and Treatment
3.4.5. Clinical Trials
3.5. Applications of AI in Clinical Trials
3.6. Challenges Associated with the Adoption of AI
3.7. Future Perspective

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. AI in Clinical Trials: AI Software and Service Providers Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters (Region)
4.2.5. Analysis by Key Offering(s)
4.2.6. Analysis by Business Model(s)
4.2.7. Analysis by Deployment Option(s)
4.2.8. Analysis by Type of AI Technology
4.2.9. Analysis by Application Area(s)
4.2.10. Analysis by Potential End-user(s)

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AiCure
5.3. Antidote Technologies
5.4. Deep 6 AI
5.5. Innoplexus
5.6. IQVIA
5.7. Median Technologies
5.8. Medidata
5.9. Mendel.ai
5.10. Phesi
5.11. Saama Technologies
5.12. Signant Health
5.13. Trials.ai

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. AI in Clinical Trials
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Number of Patients Enrolled
6.3.3. Analysis by Trial Phase
6.3.4. Analysis by Trial Status
6.3.5. Analysis by Trial Registration Year and Status
6.3.6. Analysis by Type of Sponsor
6.3.7. Analysis by Patient Gender
6.3.8. Analysis by Patient Age
6.3.9. Word Cloud Analysis: Emerging Focus Areas
6.3.10. Analysis by Target Therapeutic Area
6.3.11. Analysis by Study Design
6.3.12. Most Active Players: Analysis by Number of Clinical Trials
6.3.13. Analysis of Clinical Trials by Geography
6.3.14. Analysis of Clinical Trials by Geography and Trial Status
6.3.15. Analysis of Patients Enrolled by Geography and Trial Registration Year
6.3.16. Analysis of Patients Enrolled by Geography and Trial Status

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. AI in Clinical Trials: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Application Area
7.3.5. Analysis by Target Therapeutic Area
7.3.6. Analysis by Type of Partner
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Analysis by Geography

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. AI in Clinical Trials: List of Funding and Investments
8.3.1. Analysis by Year of Funding
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of Funding and Amount Invested
8.3.5. Most Active Players: Analysis by Amount Raised and Number of Funding Instances
8.3.6. Leading Investors: Analysis by Number of Funding Instances
8.3.7. Analysis of Amount Invested by Geography
8.3.8. Analysis of Number of Funding Instances by Geography
8.4. Concluding Remarks

9. BIG PHARMA INITIATIVES
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Analysis by Year of Initiative
9.4. Analysis by Type of Initiative
9.5. Analysis by Application Area of AI
9.6. Analysis by Target Therapeutic Area
9.7. Benchmarking Analysis: Big Pharma Players

10. AI IN CLINICAL TRIALS: USE CASES
10.1. Chapter Overview
10.2. Use Case 1: Collaboration between Roche and AiCure
10.3. Use Case 2: Collaboration between Takeda and AiCure
10.4. Use Case 3: Collaboration between Teva Pharmaceuticals and Intel
10.5. Use Case 4: Collaboration between Unnamed Pharmaceutical Company and Antidote
10.6. Use Case 5: Collaboration between Unnamed Pharmaceutical Company and Cognizant
10.7. Use Case 6: Collaboration between Cedars-Sinai Medical Center and Deep 6 AI
10.8. Use Case 7: Collaboration between GlaxoSmithKline (GSK) and PathAI
10.9. Use Case 8: Collaboration between Bristol Myers Squibb (BMS) and Concert AI

11. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEEDS IN CLINICAL TRIALS
11.1. Chapter Overview
11.2. Unmet Needs in Clinical Trials
11.3. Key Assumptions and Methodology
11.4. Key Tools / Technologies
11.4.1. Blockchain
11.4.2. Big Data Analytics
11.4.3. Real-world Evidence
11.4.4. Digital Twins
11.4.5. Cloud Computing
11.4.6. Internet of Things (IoT)
11.5. Trends in Research Activity
11.6. Trends in Intellectual Capital
11.7. Extent of Innovation versus Associated Risks
11.8. Results and Discussion
11.9. Summary

12. COST SAVING ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Overall Cost Saving Potential of AI in Clinical Trials, 2023-2035
12.3.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
12.3.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
12.3.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
12.3.4. Cost Saving Potential in Patient Recruitment, 2023-2035
12.3.5. Cost Saving Potential in Patient Retention, 2023-2035
12.3.6. Cost Saving Potential in Staffing and Administration, 2023-2035
12.3.7. Cost Saving Potential in Site Monitoring, 2023-2035
12.3.8. Cost Saving Potential in Source Data Verification, 2023-2035
12.3.9. Cost Saving Potential in Other Procedures, 2023-2035

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global AI in Clinical Trials Market, 2023-2035
13.3.1. AI in Clinical Trials Market: Distribution by Trial Phase, 2023 and 2035
13.3.2. AI in Clinical Trials Market: Distribution by Target Therapeutic Area, 2023 and 2035
13.3.3. AI in Clinical Trials Market: Distribution by End-user, 2023 and 2035
13.3.4. AI in Clinical Trials Market: Distribution by Key Geographical Regions, 2023 and 2035

14. CONCLUSION

15. EXECUTIVE INSIGHTS

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

1. AbbVie
2. Accelmed
3. Accenture
4. Acclinate
5. Actelion Pharmaceuticals
6. Adara Ventures
7. AG Mednet
8. Agent Health
9. A.I. VALI
10. AiCure
11. Aidar Health
12. AITIA
13. AKESOgen
14. AKRN Scientific Consulting (acquired by NAMSAN)
15. Alexandria Venture Investments
16. Alira Health
17. AliveCor
18. AllianceBernstein
19. Alliance for Clinical Trials in Oncology
20. Allucent
21. Alpha MD
22. ALS Association
23. Alter Venture Partners
24. Amadeus Capital Partners
25. Amber Specialty Pharmacy
26. American Society of Clinical Oncology (ASCO)
27. Amgen
28. Amgen Ventures
29. Amplify
30. Ancora.ai
31. Anthem
32. Anthemis Exponential Ventures
33. Antidote Technologies
34. Aperio
35. APEX Digital Health
36. APEX Ventures
37. Arondor
38. Artificial Intelligence in Medicine (AIM) (a subsidiary of Inspirata)
39. ArtiQ
40. Arvinas
41. Asahi Kasei
42. Ascension Ventures
43. Aspen Insights
44. Assistance Publique Hopitaux de Paris
45. AstraZeneca
46. ATAI Life Sciences
47. AV8 Ventures
48. Avalanche Venture Capital
49. Avident Health
50. Avira Digital
51. Aviva Ventures
52. Avon
53. Baird Capital
54. Baron Davis Enterprises
55. Beacon Biosignals
56. BEPATIENT
57. Beyond Celiac
58. Big Pi Ventures
59. Bioforum
60. Biofourmis
61. Bioinfogate (acquired by Clarivate)
62. Biomatics Capital
63. Biomedical Advanced Research and Development Authority (BARDA)
64. Blue Heron Capital
65. Boehringer Ingelheim
66. Boehringer Ingelheim Venture Fund (BIVF)
67. Bold Capital Partners
68. Bolton NHS Foundation Trust
69. BootstrapLabs
70. Boreal Ventures
71. Bpifrance
72. Brainomix
73. Brainpan Innvovations
74. Bridge Biotherapeutics
75. Bristol Myers Squibb (BMS)
76. Brite Health
77. Bronze Valley
78. BUDDI.AI
79. BullFrog AI
80. Cambridge Cognition
81. Canary Speech
82. Carebox
83. Carenity (acquired by EvidentIQ)
84. Carle Health
85. Carlyle
86. Casdin Capital
87. Cathay Innovation
88. Cavendish Impact Foundation (CIF)
89. Cedar Health Research
90. Celgene
91. CellCarta
92. Central Ohio Primary Care Physicians (COPC)
93. The Centre for Aging + Brain Health Innovation (CABHI )
94. Cerba Research
95. Chainlink
96. Charterhouse Capital Partners
97. Chartline Capital Partners
98. ChemAxon
99. Children's Oncology Group (COG)
100. Chimera Partners
101. Cigna Ventures
102. CIMS Global
103. Citeline ( a subsidiary of Norstella)
104. Clario
105. Clarivate
106. ClearPoint Investment Partners
107. Clinerion
108. Clinevo Technologies
109. clinicalAI
110. CliniOps
111. Clinithink
112. ClinScape
113. ClinTex
114. CMIC Group
115. Cognizant
116. Community Health Network
117. ConcertAI
118. Constant Companion
119. Creadev
120. Crestle.ai (acquired by Doc.ai)
121. Crista Galli Ventures
122. Cumulus Neuroscience
123. Curenetics
124. Curify.ai
125. CVS Health
126. Dassault Systemes
127. DataON
128. Datavant
129. DCM Ventures
130. DCVC Bio
131. Debiopharm
132. Decibel Therapeutics
133. Declaration Partners
134. Deep 6 AI
135. Deep Lens (acquired by Paradigm)
136. DeepTrial
137. Defense Health Agency
138. Dementia Discovery Fund (DDF)
139. Department of Veteran Affairs
140. Deutsche Investitions und Entwicklungsgesellschaft (DEG)
141. DiA Imaging Analysis
142. doc.ai (acquired by Sharecare)
143. Dong-A Socio Holdings
144. EBSCO Information Services
145. Echo Health Ventures
146. EDBI
147. Edison Partners
148. Eight Roads Ventures
149. eimageglobal
150. EIT Health
151. Elliott Investment Management
152. Entrepreneur First
153. Epilepsy Study Consortium
154. Ergomed
155. Erlanger Health System
156. ERYTECH
157. Espresso Capital
158. Eugene M. Lang Foundation
159. European Commission
160. European Investment Bank
161. European Regional Development Fund (ERDF)
162. Excelra
163. Experimental Cancer Medicine Centre (ECMC)
164. Experimind
165. Faber
166. fathom it group
167. FinLab EOS VC Fund
168. First Analysis Corporation
169. First Trust Capital Partners
170. Florida Cancer Affiliates
171. Folklore Ventures
172. Fosun RZ Capital
173. GE Healthcare
174. Genentech
175. General Atlantic
176. General Catalyst
177. Genoa Ventures
178. Genomenon
179. Genpro Research
180. GlaxoSmithKline (GSK)
181. Global Alzheimer's Platform Foundation
182. Gloucestershire Cancer Alliance (SWAG)
183. Google
184. GV (formerly Google Ventures)
185. Greater Gift
186. Grey Sky Venture Partners
187. Grove Ventures
188. GSR Ventures
189. Guy's and St Thomas' NHS Foundation Trust
190. H1
191. H2O.ai
192. Halo Health
193. Hambro Perks
194. Healint
195. Healthix
196. HealthMatch
197. HealthVerity
198. Hematology-Oncology Associates of Central New York (HOA)
199. Jiangsu Hengrui Pharmaceuticals
200. Herefordshire and Worcestershire Health and Care NHS Trust
201. Heritage Medical Group
202. Highline Sciences
203. HCLTech
204. Horizon Therapeutics
205. Human API
206. IBM
207. iClusion
208. ICON
209. IKJ Capital
210. iLoF
211. IMA Group
212. IMNA Solutions
213. ImpactAssets
214. Inato
215. Indegene
216. iNDX.Ai
217. Inflection Biosciences
218. Innoplexus
219. Innovaderm
220. Innovatrix Capital
221. Insight Partners
222. Insilico Medicine
223. Inspirata
224. Inspire
225. Intel
226. Intel Capital (a subsidiary of Intel)
227. Intelligencia.ai
228. Intermountain Ventures
229. Investissement Quebec
230. Iowa First Capital Fund
231. Iowa Innovation Acceleration Fund
232. IQ Capital
233. IQVIA
234. IXICO
235. Janssen Pharmaceuticals
236. Jianke
237. Johns Hopkins University
238. Johnson & Johnson
239. Karyopharm Therapeutics
240. Keosys
241. Khosla Ventures
242. King's Health Partners
243. Kinship
244. Kleiner Perkins
245. Kognitic
246. Labcorp
247. Lambda Therapeutic Research
248. LaunchCapital
249. Launch Therapeutics
250. LBO France
251. Leal Health
252. Legit.Health
253. LEO Pharma
254. Leukemia & Lymphoma Society
255. Lieber Institute for Brain Development
256. Life Image (acquired by Intelerad Medical SystemsT )
257. LifeArc
258. Lightship
259. Linguamatics (a subsidiary of IQVIA)
260. Liquid 2 Ventures
261. LMK Clinical Research Consulting
262. Lokavant (a subsidiary of Roivant Sciences)
263. LSU Health New Orleans
264. Lunar Ventures
265. M12 (formerly known as Microsoft Ventures)
266. Massachusetts General Hospital
267. Massive Bio
268. MassMutual Ventures
269. Matrix Capital Management
270. Matrix Partners
271. Maverick Ventures
272. Maxer Consulting
273. Mayfield Fund
274. Mayo Clinic
275. Mayo Clinic Ventures (a subsidiary of Mayo Clinic)
276. McKesson Ventures (a subsidiary of McKesson)
277. Medable
278. Median Technologies
279. Medica
280. Medical Research Network (MRN)
281. Medidata Solutions
282. mediri
283. Medpace
284. MEDSOFT
285. Medtronic
286. Memorial Sloan Kettering Cancer Center (MSK)
287. Mendel.ai
288. Menlo Ventures
289. Merck
290. Merck Global Health Innovation Fund (Merck GHI) (a subsidiary of Merck)
291. Microsoft
292. Millennium Technology Value Partners
293. Mitsui
294. Moderna
295. MSD Global Health Innovation Fund (MGHIF)
296. MTIP
297. Mubadala Capital
298. Nanox
299. National Cancer Institute (NCI)
300. National Institute of Allergy and Infectious Diseases (NIAID)
301. National Institute of Mental Health (NIMH)
302. National Minority Health Association (NMHA)
303. NEC
304. NEC OncoImmunity (a subsidiary of NEC)
305. NeoGenomics
306. NetraMark
307. NeuroEndocrine Cancer Australia
308. New Enterprise Associates
309. New Leaf Venture Partners
310. Nex Cubed
311. Next Level Ventures
312. nference
313. NJF Capital
314. Nor-Tech
315. North American Science Associates (NAMSA)
316. Northpond Ventures
317. Nova Discovery
318. Novartis
319. Novoic
320. Novotech
321. nQ Medical
322. Nucleai
323. NuvoAir
324. Oak HC/FT
325. Obvious Ventures
326. Ocala Oncology
327. Octopus Ventures
328. Olive Tree
329. OMRON Healthcare
330. OncoBay Clinical
331. OncoSec Medical
332. One Nucleus
333. OneStudyTeam
334. Openspace Ventures
335. Opyl
336. Oracle
337. Otium Venture
338. ?URA Health
339. Overline Venture Capital
340. Owkin
341. Oxford Finance
342. University of Oxford Innovation Fund (UOIF)
343. P1vital
344. P360
345. P3Life
346. Paige AI
347. Palisades Growth Capital
348. Pancare Foundation
349. Pangaea Data
350. Paradigm
351. Parexel
352. Parkwalk Advisors
353. Partech
354. Passage AI
355. Patchai (acquired by Alira Health)
356. PathAI
357. Patient iP
358. PatientPoint
359. PatienTrials
360. Patiro
361. Pear Therapeutics
362. Pepgra
363. Perceiv AI
364. Perceptive Advisors
365. Perthera.ai
366. Pfizer
367. Pfizer Ventures (a subsidiary of Pfizer)
368. Pharmamodelling
369. Phastar
370. phaware
371. Phesi
372. physIQ
373. Plug and Play Ventures
374. Point72 Ventures
375. Population Health Partners
376. PPC (merged with Novotech)
377. PRA Health Sciences
378. Precipio
379. Prime Capital
380. Pritzker Group
381. ProofPilot
382. Propeller Health
383. Protocols.io
384. PWNHealth
385. Qmetrics Technologies
386. Qualcomm Ventures
387. Quality Cancer Care Alliance Network (QCCA)
388. Quibim
389. Quiet Capital
390. Qure.ai
391. Qwince
392. Radical Ventures
393. RadMD (acquired by Medica Group)
394. Raylytic
395. re.Mind Capital
396. RealTime Software Solutions
397. Red Abbey Labs
398. Reify Health
399. Remarque Systems
400. Renmin Hospital of Wuhan University
401. Rev1 Ventures
402. Revo Capital
403. Revolution Growth
404. Risklick
405. Rittenhouse Ventures
406. Roche
407. Roivant Sciences
408. Royal Philips
409. Rural Vitality Fund
410. Rymedi
411. Saama Technologies
412. San Raffaele Hospital
413. Sanofi
414. Sanofi Ventures (a subsidiary of Sanofi)
415. Scale Ventures
416. Science37
417. Scipher Medicine
418. Self-Care Catalysts
419. Semicrol
420. sensedat
421. Sensyne Health
422. Sequoia India
423. Serena and Fly Ventures
424. ServiceNow
425. Servier
426. SGInnovate
427. Shandong University
428. Sierra Ventures
429. Sigmasoft
430. Signant Health
431. Silicon Valley Bank (SVB)
432. SimBioSys
433. Singtel Innov8
434. SiteGround Capital
435. SiteRx
436. Sixth Street
437. Small Business Innovation Research (SBIR)
438. Smedvig Capital
439. SoftBank Vision Fund
440. Somerset
441. Sopris Capital
442. SOSV
443. Sourcia
444. Southern Oncology Specialists
445. Sozo Ventures
446. SpringRock Ventures
447. Square Peg
448. Square Peg Capital
449. Stanford Angels
450. Stratus
451. SubjectWell
452. Sway Ventures
453. SyMetric
454. Symphony Clinical Research (acquired by ICON)
455. SymphonyAI
456. Syneos Health
457. Synetro
458. Synexus
459. System Applications and Products in Data Processing (SAP)
460. T. Rowe Price
461. Taliaz
462. Talkdesk
463. Tamarind Hill Fund
464. Teal Ventures
465. Tech Transfer UPV
466. TEDCO's Seed Fund
467. Tempus
468. Tencent Holdings
469. Tenthpin
470. TeraRecon
471. TFS Services
472. The Angels' Forum
473. ThoughtSphere
474. THREAD
475. Tiger Global Management
476. Timberline Holding
477. TissueTech
478. Translational Drug Development (TD2)
479. TransPerfect Life Sciences
480. Trialbee
481. Trials.ai (acquired by ZS Associates)
482. TrialSense
483. Tribeca Venture Partners
484. TriNetX
485. TT Capital Partners
486. TTi Health Research & Economics
487. U.S. Food and Drug Administration (FDA)
488. U.S. Veteran's Affairs
489. UCB Biopharma
490. UK Future Fund
491. Underscore Venture Capital
492. UnityPoint Health Ventures
493. University of California
494. University of Pennsylvania
495. University of Pittsburgh
496. Unlearn.AI
497. Vastrax
498. VeriSIM
499. VersaTrial
500. Vertex Ventures
501. Veterans Prostate Cancer Awareness (VPCa)
502. VIDA
503. Viroclinics-DDL (acquired by Cerba HealthCare)
504. VirTrial
505. Vivoryon Therapeutics
506. Viz.ai
507. WallachBeth Capital
508. WCG Clinical
509. Wefight
510. Wiley
511. Winterlight Labs
512. Wittington Ventures
513. Worldwide Clinical Trials
514. WP Global Partners
515. XpertPatient
516. Zola Global Investors
517. ZS Associates

For more information about this report visit https://www.researchandmarkets.com/r/c67zyz

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets